Bojungikki-Tang
Biliary Tract Cancer
Kil Yeon LeePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
65 Active assets in the Biliary Tract Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC | Phase 3 | BB |
Epirubicin Merck Sharp & Dohme LLC | Phase 3 | BB |
Cyclophosphamide Zhejiang University | Phase 3 | BB |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | BB |
Calcium folinate pentahydrate Shenzhen Xinhe Biomedical | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Bojungikki-Tang is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →